Multiple Sclerosis

Drug under Investigation:  ABT-874

Purpose of Study:  To determine the safety and efficacy associated with 200mg of ABT-874 administered weekly subcutaneously vs 200mg every other week vs placebo over a period of 24 weeks in subjects with active RRMS or SPMS.

Inclusion Criteria:

• Age 18 to 60 years old
• Diagnosed with active RRMS (Relapsing-Remitting) or SPMS (Secondary Progressive), with at least one medically documented relapse within 12 months prior to screening
• Must meet study-required criteria based on MRI scans at screening and baseline visits
• Interferon, glatiramer acetate therapy, and natalizumab should be washed out for at least 3 months prior to dosing with study drug
• Women of childbearing potential must agree to use 2 forms of contraception during the duration of the study

Exclusion Criteria:

• PPMS (Primary progressive)
• Use of immunosuppressive therapy within 6 months of enrolling
• Use of mitoxantrone treatment within 12 months of enrolling
• Use of systemic corticosteroid therapy within 1 month prior to first screening MRI
• Severe, recurrent, or persistent infections or pneumonia or tuberculosis
• History of lymphoma or leukemia, cutaneous squamous-cell or basal cell carcinoma, or other malignancy
• Exacerbation of asthma requiring hospitalization within 10 years of enrolling
• Recent history of substance abuse or psychiatric illness
• Transfusion of any blood product received within 2 months of enrolling
• Restricted concomitant medications: Avonex®, Betaseron®, Copaxone®, Cytoxan®, Gamimune®, Gammagard®, Sandoglobulin®, Iveegam®, Imuran®, Leukeran®, Rebif®, Sandimmune®, Neoral®, Tysabri®, Methotrexate, and any investigative agents

If you qualify, all study related care is provided at no charge including:

• Study visits and study related procedures/tests
• Laboratory tests
• Study medication
• Financial compensation for time/travel expenses

Inclusion/Exclusion Criteria Must Be Met